doi:10.16150/j.1671-2870.2018.02.018

[1] Arber DA, Orazi A, Hasserjian R, et al.he 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
[2] Bennett JM, Catovsky D, Daniel MT, et al.Proposals for the classification of the myelodysplastic syndromes[J]. Br J Haematol,1982,51(2):189-199.
[3] Guru Murthy GS, Dhakal I, Mehta P.Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States[J]. Leuk Lymphoma,2017,58(7):1648-1654.
[4] Srour SA, Devesa SS, Morton LM, et al.Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12[J]. Br J Haematol,2016,174(3):382-396.
[5] Solary E, Itzykson R.How I treat chronic myelomonocy-tic leukemia[J]. Blood,2017,130(2):126-136.
[6] Patnaik MM, Tefferi A.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management[J]. Am J Hematol,2016,91(6):631-642.
[7] Pophali PA, Patnaik MM.The role of new tyrosine kinase inhibitors in chronic myeloid leukemia[J]. Cancer J,2016, 22(1):40-50.
[8] Patnaik MM, Lasho TL, Finke CM, et al.Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis[J]. Am J Hematol,2016,91(3):E12-E14.
[9] Bain BJ.What is a promonocyte?[J]. Am J Hematol,2013,88(10):919.
[10] Tang G, Zhang L, Fu B, et al.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution[J]. Am J Hematol,2014, 89(8):813-818.
[11] Such E, Cervera J, Costa D, et al.Cytogenetic risk stratification in chronic myelomonocytic leukemia[J]. Haematologica,2011,96(3):375-383.
[12] Patnaik MM, Itzykson R, Lasho TL, et al.ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients[J]. Leukemia,2014,28(11):2206-2212.
[13] Jankowska AM, Makishima H, Tiu RV, et al.Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A[J]. Blood,2011,118(14):3932-3941.
[14] Smith AE, Mohamedali AM, Kulasekararaj A, et al.Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value[J]. Blood,2010,116(19):3923-3932.
[15] Itzykson R, Solary E.An evolutionary perspective on chronic myelomonocytic leukemia[J]. Leukemia,2013,27(7):1441-1450.
[16] Patnaik MM, Tefferi A.Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia[J]. Blood Cancer J,2016,6:e393.
[17] Talati C, Zhang L, Shaheen G, et al. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis[J]. Blood,2017 Mar 30,129(13):1881-1883.
[18] Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al.Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia[J]. Blood,2015,125(23):3618-3626.
[19] Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood,2009,114(5):937-951.
[20] Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J]. Cancer,2008,113(6):1351-1361.
[21] Such E, Germing U, Malcovati L, et al.Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia[J]. Blood,2013,121(15):3005-3015.
[22] Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes[J]. Leukemia,2013,27(7):1504-1510.
[23] Onida F, Barosi G, Leone G, et al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups[J]. Haematologica,2013 Sep,98(9):1344-1352.
[24] Barosi G, Birgegard G, Finazzi G, et al.A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European Leukemia Net(ELN) consensus process[J]. Br J Haematol,2010,148(6):961-963.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 14

Recommended Articles

Metrics

Comments

[1]	GAO Yanting, ZHAO Jinyan, WANG Juan, LI Jia, XU Wen, LI Li, LIN Lihui. Analysis of bone marrow lymphocyte subsets in patients with acute myeloid leukemia and its clinical significance [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 407-413.
[2]	PENG Zhenping, XIANG Xixi, ZHANG Sujiang, LI Jiaming. Chronic neutrophilic leukemia with leukemia-like reaction as the first-onset manifestation: a report of 2 cases and literature review [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 122-128.
[3]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(05): 585-587.
[4]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(06): 718-722.
[5]	ZHU Qingfeng, HU Xiaoli, ZHU Jianyi, LANG Wenjing, ZHONG Jihua, CHEN Fangyuan. Study on mechanism of synergistic effect of ASP2215 combined with SAHA on FLT3-ITD mutant cell line [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 538-546.
[6]	BAO Pingping, WU Chunxiao, ZHANG Minlu, GU Kai, XIANG Yongmei, PENG Peng, GONG Yangming, SHI Liang, ZOU Zhen.. Epidemiological features of major subtypes of leukemia and its incidence trends in Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 484-491.
[7]	WANG Shu, ZHANG Yunxiang, SUI Jingni, LU Jing, FAN Huiyong, WANG Chao, CHEN Bing.. Analysis of additional mutation pattern accompanied with CEBPA mutations in patients with the cytogenetically normal acute myeloid leukemia [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 498-503.
[8]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 1-2.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 3-6.
[10]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 7-11.
[11]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 12-16.
[12]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 17-26.
[13]	. [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 27-31.
[14]	ZHU Jianyi, LANG Wenjing, CHEN Fangyuan, XU Zhuoran, SHEN Lijing, ZHONG Jihua. Effect of arsenic trioxide on EVI1 gene in regulating hematopoietic transcription factors in vitro [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 42-47.